Telemetry Investments’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-23,058
| Closed | -$112K | – | 72 |
|
|
2020
Q1 | $112K | Sell |
23,058
-12,200
| -35% | -$79.1K | 0.39% | 45 |
|
|
2019
Q4 | $375K | Sell |
35,258
-4,742
| -12% | -$47.1K | 1.25% | 26 |
|
|
2019
Q3 | $416K | Buy |
40,000
+6,000
| +18% | +$78.5K | 1.2% | 23 |
|
|
2019
Q2 | $521K | Sell |
34,000
-16,000
| -32% | -$231K | 0.4% | 41 |
|
|
2019
Q1 | $642K | Buy |
50,000
+8,412
| +20% | +$95.1K | 0.33% | 43 |
|
|
2018
Q4 | $395K | Buy |
+41,588
| New | +$539K | 0.25% | 86 |
|
|
2018
Q3 | – | Sell |
-12,050
| Closed | -$193K | – | 163 |
|
|
2018
Q2 | $193K | Sell |
12,050
-6,450
| -35% | -$115K | 0.07% | 113 |
|
|
2018
Q1 | $283K | Sell |
18,500
-6,500
| -26% | -$101K | 0.11% | 100 |
|
|
2017
Q4 | $390K | Buy |
25,000
+6,500
| +35% | +$86.9K | 0.15% | 80 |
|
|
2017
Q3 | $205K | Sell |
18,500
-6,500
| -26% | -$61.1K | 0.07% | 127 |
|
|
2017
Q2 | $230K | Buy |
25,000
+1,470
| +6% | +$12.3K | 0.11% | 95 |
|
|
2017
Q1 | $201K | Sell |
23,530
-1,486
| -6% | -$13.5K | 0.09% | 99 |
|
|
2016
Q4 | $268K | Buy |
25,016
+2,016
| +9% | +$24.4K | 0.15% | 77 |
|
|
2016
Q3 | $249K | Sell |
23,000
-19,121
| -45% | -$155K | 0.16% | 73 |
|
|
2016
Q2 | $285K | Sell |
42,121
-19,123
| -31% | -$121K | 0.15% | 72 |
|
|
2016
Q1 | $285K | Sell |
61,244
-18,756
| -23% | -$91.6K | 0.08% | 77 |
|
|
2015
Q4 | $505K | Buy |
80,000
+3,000
| +4% | +$24.3K | 0.17% | 79 |
|
|
2015
Q3 | $680K | Sell |
77,000
-2,000
| -3% | -$21K | 0.29% | 75 |
|
|
2015
Q2 | $930K | Buy |
79,000
+24,000
| +44% | +$333K | 0.42% | 53 |
|
|
2015
Q1 | $796K | Buy |
55,000
+18,000
| +49% | +$275K | 0.44% | 45 |
|
|
2014
Q4 | $631K | Buy |
+37,000
| New | +$534K | 0.39% | 65 |
|
Telemetry Investments's STML Position: Q2 2020 in Review
Telemetry Investments sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 23,058 shares — an estimated $112K sold.
Telemetry Investments first reported a position in STML in Q4 2014 and held it in 21 quarters. The position peaked at $930K in Q2 2015. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Telemetry Investments reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Telemetry Investments sold 23,058 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $112K.
- Telemetry Investments first reported a position in Stemline Therapeutics, Inc. in Q4 2014 and held it in 21 quarters.
- Telemetry Investments's Stemline Therapeutics, Inc. position peaked at $930K in Q2 2015.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Telemetry Investments's 13F filing for Q2 2020, filed 14 Aug 2020.